Eosinophilic oesophagitis, an inflammatory condition that is probably caused by food allergies or other environmental triggers, can be misdiagnosed as gastrooesophageal reflux disease. In adults, for example, symptoms include dysphagia, bolus obstruction and chest pain that is related to swallowing, heartburn and regurgitation.

Recently Dr Falk Pharma UK launched Jorveza, an orodispersible tablet containing budesonide which, the company says, “is specifically designed to deliver directly to the inflammation within the oesophageal mucosa”. The company describes Jorveza as “the first globally licensed drug” approved for eosinophilic oesophagitis.

Recommended

Keith Ridge to lead NHS over-prescribing review

The review will look to address ‘problematic polypharmacy’ and the management of non-reviewed repeat prescri...

Hancock warns HCPs against stockpiling

Healthcare professionals should not build stockpiles of their own and any “over-ordering” will be investigat...




This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Magazine's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.